Walleye Capital
ELVN icon

Walleye Capital’s Enliven Therapeutics ELVN Stock Holding History

Walleye Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,827
Closed -$1.48M – 4848
2026
Q1 		$1.48M Buy
+37,827
New +$1.05M 0.01% 1717
2024
Q4 		– Sell
-99,416
Closed -$2.54M – 5007
2024
Q3 		$2.54M Buy
+99,416
New +$2.3M 0.01% 1730
2024
Q2 		– Sell
-56,763
Closed -$998K – 5689
2024
Q1 		$998K Buy
+56,763
New +$871K ﹤0.01% 2591
2022
Q1 		– Sell
-19,295
Closed -$174K – 2367
2021
Q4 		$174K Sell
19,295
-22,619
-54% -$297K 0.01% 1521
2021
Q3 		$684K Buy
+41,914
New +$871K 0.02% 644
2021
Q2 		– Sell
-8,426
Closed -$284K – 1386
2021
Q1 		$284K Buy
+8,426
New +$428K 0.02% 804

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Walleye Capital's ELVN Position: Q2 2026 in Review

Walleye Capital sold out of Enliven Therapeutics (ELVN) in Q2 2026, closing a stake of 37,827 shares — an estimated $1.48M sold.

Walleye Capital first reported a position in ELVN in Q1 2021 and held it in 6 quarters. The position peaked at $2.54M in Q3 2024. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Walleye Capital reported no remaining Enliven Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 37,827 Enliven Therapeutics shares in Q2 2026, an estimated $1.48M.
  • Walleye Capital first reported a position in Enliven Therapeutics in Q1 2021 and held it in 6 quarters.
  • Walleye Capital's Enliven Therapeutics position peaked at $2.54M in Q3 2024.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.